CC chemokines induce the generation of killer cells from CD56(+) cells
CC chemokines induce the generation of killer cells from CD56(+) cells
复制标题
DOI：
10.1002/eji.1830260207
复制
发表时间：
1996-02-01
影响因子：
5.4
通讯作者：
Schall, TJ
中科院分区：
文献类型：
--
作者：
Maghazachi, AA;AlAoukaty, A;Schall, TJ
我们在此描述，CC趋化因子成员表现出趋化作用以外的生物学活性。巨噬细胞炎性蛋白（MIP）-1α、MIP - 1β、单核细胞趋化蛋白 - 1和RANTES，但不包括白细胞介素（IL）- 8，可诱导产生细胞毒性细胞，在此将其命名为CHAK（CC趋化因子激活的杀伤细胞），以区别于IL - 2激活的（LAK）细胞。与IL - 2一样，CC趋化因子能够诱导杀伤细胞的增殖和活化。虽然将CC趋化因子与CD4⁺或CD8⁺细胞一起培养不会产生CHAK活性，但所有CC趋化因子在与CD56⁺细胞一起培养时都能够诱导CHAK活性，这表明主要效应细胞是NK细胞。然而，其他细胞类型，如CD4⁺或CD8⁺的存在，对于诱导CD56⁺细胞的增殖是必要的。抗IL - 2和抗干扰素 - γ，但不包括抗IL - 1β、抗肿瘤坏死因子 - α、抗IL - 8或抗粒细胞/单核细胞集落刺激因子，可抑制RANTES诱导的尼龙毛柱非贴壁细胞的增殖，这证实了T细胞衍生因子在诱导这些细胞增殖中的作用。我们的研究结果对于在癌症和免疫缺陷患者的治疗中利用CHAK细胞可能具有重要的临床应用价值。
We describe here that members of the CC chemokines exhibit biological activities other than chemotaxis. Macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta monocyte chemoattractant protein-1 and RANTES, but not interleukin (IL)-8. induce the generation of cytolytic cells, designated here as CHAK (CC chemokine-activated killer) cells to distinguish them from IL-2-activated (LAK) cells. Like IL-2, CC chemokines. can induce the proliferation and activation of killer cells. While incubating CC chemokines with CD4(+) or CD8(+) cells did not generate CHAK activity, all CC chemokines were capable of inducing CHAK activity upon incubating with CD56(+) cells, suggesting that the primary effecters are NK cells. However. the presence of other cell types, such as CD4(+) or CD8(+), are necessary to induce the proliferation of CD56(+) cells. Confirming the involvement of T cell-derived factors in inducing the proliferation of these cells, anti-IL-2 and anti-interferon-gamma, but not anti-IL-1 beta, anti-tumor necrosis factor-alpha. anti-IL-8, or anti-granulocyte/monocyte-colony-stimulating factor inhibited RANTES-induced proliferation of nylon wool column nonadherent cells. Our results may have important clinical applications for the utilization of CHAK cells in the treatment of cancer and immunodeficient patients.